The New York Times profiled Joy Milne, a super-smeller who can detect Parkinson’s disease and the co-author of several papers on the topic.
Cold and heat exposure in infancy appeared to influence white matter development in children. (Nature Climate Change)
The Global CEO Initiative on Alzheimer’s Disease recommended performance standards for blood biomarker tests of amyloid pathology in primary and secondary care. (Nature Reviews Neurology)
World Trade Center responders were at risk for early-onset dementia, with toxic dust exposure after the 9/11 attack possibly playing a role. (JAMA Network Open)
Tau PET outperformed MRI and amyloid PET as a standalone prognostic marker for progression from mild cognitive impairment to dementia. (JAMA Neurology)
The first generic version of deflazacort (Emflaza) to treat Duchenne muscular dystrophy (DMD) was approved, Cranbury Pharmaceuticals announced.
Pfizer reported that its investigational gene therapy for DMD, fordadistrogene movaparvovec, did not meet its primary endpoint of improvement in motor function in a phase III trial.
Takeda said investigational soticlestat missed primary endpoints of seizure reduction in phase III trials of Dravet syndrome and Lennox-Gastaut syndrome.
Angiotensin receptor blockers (ARBs) were linked with a lower incidence of new-onset epilepsy in people with hypertension compared with other antihypertensive drugs. (JAMA Neurology)
Prolonged exposure to elevated depressive symptoms starting in young adulthood led to worse cognitive function over 20 years. (Neurology)
A smartwatch and smartphone assessed early Parkinson’s symptoms. (NPJ Parkinson’s)
Brain research has tremendous promise but raises ethical questions that demand more than just regulatory compliance, NIH researchers said in a New England Journal of Medicine essay.
Please enable JavaScript to view the